The ALDOB gene, which contributed the most to the signature and was more sensitive to most medicines, was selected for in vitro experiments to verify its effect on prostate cancer cells under hypoxia (Supplementary File 10). This evidence concerns the gene ALDOB and prostate carcinoma.